Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Zenas BioPharma Inc. | Obexelimab - (SApHiAre) | Warm Autoimmune Hemolytic Anemia | Phase 3 | Ongoing | Intravenous | Hematology |
| Zenas BioPharma Inc. | Obexelimab - (MoonStone) | Relapsing Multiple Sclerosis (RMS) | Phase 3 | Trial Planned | Intravenous | Neurology |
| Zenas BioPharma Inc. | Obexelimab - (SunStone) | Systemic Lupus Erythematosus (SLE) | Phase 2 | Ongoing | Intravenous | Immunology |
| Zentalis Pharmaceuticals Inc. | Azenosertib - (ASPENOVA) | Platinum-resistant ovarian cancer (PROC) | Phase 3 | Trial Planned | oral | Oncology |
| Zentalis Pharmaceuticals Inc. | Azenosertib (ZN-c3) + ZEJULA (Niraparib) - (DENALI) | Platinum Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer | Phase 2 | Data Released | Oral | Oncology |
| Zentalis Pharmaceuticals Inc. | Azenosertib (ZN-c3) - (TETON) | Uterine serous carcinoma (USC) | Phase 2 | Ongoing | oral | Oncology |
| Zevra Therapeutics Inc. | KP484 | ADHD | Phase 3 | Trial Planned | Oral | Psychiatric |
| Zevra Therapeutics Inc. | EDSIVO (celiprolol) - (DiSCOVER) | Vascular Ehlers-Danlos Syndrome | Phase 3 | Ongoing | Oral | Genetic Disorder |
